Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

NCT04387292 | Completed

• 1 other identifier: MMT_2020_12
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components:

• An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular
• A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases.
• A thromboembolic action

Conditions

COVID19; Ophthalmopathy

Keywords

COVID19

Outcome Measures

Primary Outcomes (1)

• Description of the ophthalmological problems observed

  Multimodal ophthalmologic imaging

  6 months after discharge of hospitalization

Study Arms (1)

Ophthalmologic exam

EXPERIMENTAL

Procedure: Ophthalmologic exam

Interventions

Ophthalmologic exam PROCEDURE

* Visual acuity (ETDRS exam) * Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test * Lipiview * Eye pressure measurement (air tonometer) * Wide field retinophotography * Multicolor and auto-fluorescence retinophotography * Indocyanine green retinal angiography * Optical coherence tomography (OCT) B posterior pole scan * OCT Angiography (OCT-A) of the optic nerve and posterior pole * Adaptive optics * Visual field (Humphrey)

Ophthalmologic exam

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or PCR- Polymerase chain reaction)

You may not qualify if:

• Pregnant or breastfeeding woman

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (1)

Fondation A de Rothschild

Paris, France, 75019, France

Location

Related Publications (1)

• Abdelmassih Y, Azar G, Bonnin S, Scemama Timsit C, Vasseur V, Spaide RF, Behar-Cohen F, Mauget-Faysse M. COVID-19 Associated Choroidopathy. J Clin Med. 2021 Oct 13;10(20):4686. doi: 10.3390/jcm10204686.

  PMID: 34682810 RESULT

MeSH Terms

Conditions

COVID-19; Eye Diseases

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Martine MAUGET FAYSSE, MD

  Fondation A. de Rothschild

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2020
• First Posted: May 13, 2020
• Study Start: September 7, 2020
• Primary Completion: January 21, 2021
• Study Completion: May 15, 2021
• Last Updated: January 6, 2026

Record last verified: 2021-08

Locations

FR (1)